Relay Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
Relay Therapeutics, Inc. (RLAY) filed a Current Report on Form 8-K on August 7, 2025. The filing announces the company's financial results for the quarter ended June 30, 2025. The full details of these results are contained in a press release furnished as Exhibit 99.1 to this report.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. Investors must refer to the attached press release (Exhibit 99.1) for these figures.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance compared to the prior comparable period. Such analysis is contained within the referenced press release.
Guidance, Outlook, and Risks
This 8-K filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, directing readers to the press release for substantive content.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2025 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if there were any changes to the company's financial guidance or outlook.